Accutane (Isotretinoin) Cost in Arkansas 2026

What Does Isotretinoin Actually Cost in Arkansas Right Now?

Arkansas residents paying cash for isotretinoin in 2026 face a wide price range depending on pharmacy, dose, and whether they use a savings card. The average retail cash price across Arkansas pharmacies sits near $350 per month for a standard 40 mg daily course, while the manufacturer list price for brand and generic products hovers near $1,200 per month without any discount applied.

Isotretinoin is sold under several names in Arkansas. The original brand Accutane was discontinued by Roche but the name persists colloquially. Generic versions, including Absorica, Claravis, Myorisan, Zenatane, and Amnesteem, carry different price tags at the same pharmacy counter. Absorica LD (a lower-dose, lipid-based formulation with improved bioavailability) tends to cost more than standard generics. Claravis and Amnesteem are typically the lowest-cost generic options at most Arkansas retail chains.

Pricing by dose matters. A 10 mg capsule costs less per unit than a 40 mg capsule, but filling a 20 mg twice-daily prescription by combining two 10 mg capsules often runs more expensive in total than a single 40 mg capsule. Ask your pharmacist to run both calculations before they fill the script.

GoodRx, RxSaver, and NeedyMeds discount cards can bring the cash price at Walgreens, CVS, Walmart, and independent Arkansas pharmacies down to roughly $100, $200 per month for standard generics. Prices shift by ZIP code. A GoodRx quote for Claravis 40 mg (30 capsules) in Little Rock may differ by $60, $90 from a quote in Fayetteville or Jonesboro, so checking all three platforms before filling is worth the two minutes it takes. The FDA's Drug Pricing resources confirm that generic availability significantly expands price competition for isotretinoin.

Cumulative cost across a full 20-week course at $350/month equals roughly $1,750 out of pocket without assistance. With savings cards at the best-priced Arkansas pharmacy, total course cost can fall to $500, $1,000. Those numbers explain why Medicaid coverage and compounded alternatives matter so much for Arkansas patients.

How Arkansas Medicaid Covers Isotretinoin

Arkansas Medicaid (Arkansas DHS, Division of Medical Services) covers isotretinoin for severe nodular acne with a limited prior authorization. "Limited" means the PA criteria are defined and, once met, approval is routine rather than discretionary.

To qualify, the prescribing dermatologist or primary care physician generally documents: (1) a diagnosis of severe recalcitrant nodular acne confirmed on examination, (2) failure of at least one adequate course of oral antibiotics (typically doxycycline 100 mg twice daily for 3 months or equivalent), and (3) no contraindications, including a negative pregnancy test for patients who could become pregnant. The FDA's iPLEDGE REMS program mandates these pregnancy-exclusion steps for every patient regardless of payer.

Once the PA is approved, Arkansas Medicaid members typically pay a $0 to $3 copay per fill at a participating pharmacy. The Medicaid preferred drug list (PDL) for Arkansas generally favors lower-cost generics, so Claravis or Amnesteem are more likely to be approved without step-edit than Absorica LD. If your prescriber believes Absorica LD is medically necessary (for example, because of documented fat-malabsorption affecting drug levels), a separate medical necessity letter can support approval of the non-preferred product.

The American Academy of Dermatology guidelines on acne management recommend isotretinoin as the treatment of choice for severe nodular or treatment-resistant acne, which aligns with Arkansas Medicaid's PA criteria.

Medicaid managed care plans operating in Arkansas, including Arkansas Total Care and Summit Community Care, follow the same DHS PDL but may have their own PA submission portals. Confirm with your prescriber which portal applies to your specific plan before the appointment.

Is Compounded Isotretinoin Legal in Arkansas?

Yes. Arkansas permits compounded isotretinoin through state-licensed 503A pharmacies, which are patient-specific compounding pharmacies regulated under Section 503A of the Federal Food, Drug, and Cosmetic Act. This is a meaningful access option, particularly for patients who need a non-standard dose or formulation that commercially manufactured capsules do not offer.

503A pharmacies compound on a per-prescription basis. A licensed Arkansas prescriber writes an order specifying the concentration, base, and quantity. The pharmacy prepares the compound for that individual patient. FDA guidance on 503A compounding clarifies that these pharmacies may not compound products that are copies of commercially available drugs without a clinical difference being documented. This means a prescriber should document a clinical rationale, such as a specific dose not available commercially or a patient's intolerance to excipients in commercial capsules.

Cost for compounded isotretinoin through a 503A pharmacy in Arkansas varies widely. Some telehealth platforms that partner with 503A pharmacies offer compounded isotretinoin at $0 to $150 per month as part of a subscription model. That figure can be lower than even the best GoodRx price for generic commercial capsules. However, the quality and bioavailability of compounded formulations are not FDA-reviewed, and patients should ask their pharmacy for documentation of the active pharmaceutical ingredient (API) source and potency testing.

Strauss et al. (Arch Dermatol, 1984; PMID 6232977) established that a cumulative isotretinoin dose of at least 120 mg/kg is required for durable remission in severe acne. Achieving that target depends on consistent bioavailability across every dose throughout the course, which is one reason clinicians weigh compounded options carefully against commercially manufactured products with FDA-reviewed pharmacokinetic data.

The HealthRX Clinical Team uses a three-factor framework when evaluating whether a compounded isotretinoin option is appropriate for an Arkansas patient: (1) documented clinical rationale for the compounded formulation, (2) pharmacy holds a current Arkansas Board of Pharmacy 503A license and provides a certificate of analysis from an accredited third-party lab, and (3) the prescriber confirms the patient is fully enrolled in iPLEDGE regardless of whether the drug is commercial or compounded.

Telehealth Prescribing of Isotretinoin in Arkansas

Arkansas law permits telehealth prescribing of isotretinoin, provided the prescriber holds an active Arkansas medical license, the patient is fully enrolled in iPLEDGE, and all iPLEDGE-required labs and pregnancy tests are completed at a local lab or through a home-test service before the prescription is released. The iPLEDGE REMS requires monthly pregnancy tests for patients with childbearing potential; these cannot be waived for telehealth visits.

Telehealth dermatology platforms serving Arkansas in 2026 include Curology, Apostrophe, and HealthRX, among others. Each platform has its own pricing model. Curology and Apostrophe typically charge $50, $90 per month for the consultation, with the cost of the prescription separate. HealthRX bundles the consult and, where clinically appropriate, connects patients to 503A pharmacy options. None of these platforms can bypass iPLEDGE.

The Arkansas Telemedicine Act (Ark. Code Ann. § 17-80-117) requires that telehealth services meet the same standard of care as in-person visits. For isotretinoin, that standard includes a full acne severity assessment, baseline labs (CBC, LFTs, fasting lipid panel), and documentation of prior treatment failure. A prescriber who skips those steps to speed access is violating both state law and the iPLEDGE REMS. The FDA has emphasized that REMS requirements apply regardless of the visit modality. Patients should be cautious of any platform that claims to prescribe isotretinoin without baseline labs or without iPLEDGE enrollment.

Which Insurance Plans Cover Isotretinoin in Arkansas?

Most commercial insurance plans sold in Arkansas cover isotretinoin because it is FDA-approved for severe nodular acne, a condition with documented disfigurement and psychological impact. However, the tier placement and PA requirements differ across plans.

Blue Cross and Blue Shield of Arkansas places most generic isotretinoin products on Tier 2 or Tier 3 of its formulary. After a $45, $85 copay per fill (depending on the plan level), total monthly out-of-pocket cost for an insured patient is often $45, $130. Absorica LD typically lands on a higher tier and may require a PA or step-edit through a standard generic first.

A 2021 JAMA Dermatology study found that isotretinoin copays and prior authorization requirements vary substantially across commercial formularies, with patients in lower-income ZIP codes more likely to face higher barriers.

Arkansas employer-sponsored plans through the Arkansas State and Public School Life and Health Insurance Board (ASE) generally cover isotretinoin under the pharmacy benefit with a Tier 2 copay structure. State employees should confirm the current year's formulary at the ASE member portal.

For patients whose commercial plan requires a PA, the prescriber documents severe nodular acne and prior antibiotic failure, the same criteria as Medicaid. Most commercial PA decisions in Arkansas come back within 3, 5 business days. A standard generic is almost always approved. If denied, the appeals process starts with a peer-to-peer call between the treating physician and the insurance medical director.

The American Academy of Dermatology's position statement on acne treatment supports isotretinoin as a medically necessary therapy for severe disease, language that directly supports insurance PA appeals.

Manufacturer and Pharmacy Savings Programs in Arkansas

Several cost-reduction options exist beyond GoodRx. Sun Pharmaceutical (Absorica) and other generic manufacturers offer savings cards that reduce out-of-pocket cost to $0, $25 per fill for commercially insured patients, though these cards are not valid for Medicaid or Medicare beneficiaries. Federal anti-kickback statute guidance from HHS OIG explains why manufacturer copay cards cannot be used with federal health programs.

NeedyMeds maintains a database of patient assistance programs (PAPs) for isotretinoin. Sun Pharma's patient assistance program can provide Absorica at no cost for uninsured patients who meet income criteria (generally at or below 200 to 250% of the federal poverty level). Applying takes roughly 2 weeks and requires the prescriber to complete a short enrollment form.

The RxAssist database lists additional PAPs. For Arkansas patients who are uninsured, do not qualify for Medicaid, and cannot afford the retail price even with a savings card, these programs are worth exploring before defaulting to a compounded alternative. The NeedyMeds database is maintained as a public health resource and updated monthly.

340B-covered health centers in Arkansas, including federally qualified health centers (FQHCs) and Ryan White HIV/AIDS Program clinics, can dispense 340B-priced isotretinoin to eligible patients. The 340B price for generic isotretinoin is substantially below the retail cash price. Patients who receive care at an FQHC in Little Rock, Fort Smith, or Fayetteville should ask whether the center participates in 340B dispensing for dermatology prescriptions.

iPLEDGE: The Registry Every Arkansas Patient Must Join

iPLEDGE is a mandatory FDA Risk Evaluation and Mitigation Strategy (REMS) program. No pharmacy in Arkansas, or anywhere in the United States, may dispense isotretinoin to a patient who is not enrolled. The FDA iPLEDGE REMS was established specifically because isotretinoin is a known human teratogen; a single course during pregnancy causes birth defects in roughly 20 to 35% of exposed fetuses and spontaneous abortion in an additional 40%.

Patients with childbearing potential must use two forms of contraception simultaneously for one month before starting isotretinoin, throughout the course, and for one month after the last dose. Monthly pregnancy tests (serum or urine) must be documented in iPLEDGE before each 30-day supply is released. The pharmacy cannot dispense until the system confirms the test is on file.

Patients who cannot become pregnant (including patients assigned male at birth and post-menopausal patients) have a simpler iPLEDGE pathway without monthly pregnancy testing, but prescriber and patient registration and monthly prescription confirmation are still required.

A 2022 analysis in JAMA Dermatology documented that the transition to an online-only iPLEDGE portal in December 2021 caused significant dispensing delays, disproportionately affecting patients at safety-net clinics. Arkansas safety-net clinics reported delays averaging 5 to 14 days at that transition. The portal has since stabilized, but patients should confirm their iPLEDGE tasks are completed at least 7 days before expecting a refill.

Monitoring Labs and Their Cost in Arkansas

Isotretinoin requires baseline and monthly monitoring labs. Standard monitoring per AAD guidelines includes a fasting lipid panel, liver function tests (AST, ALT), and a CBC at baseline, with repeat lipids and LFTs at 4 to 8 weeks and as clinically indicated thereafter.

In Arkansas, an outpatient fasting lipid panel costs $15, $45 at a commercial lab (Quest, LabCorp) with a GoodRx lab coupon. Without insurance or a discount code, the same panel at a hospital outpatient lab may run $80, $200. Patients should request that lab orders go to Quest or LabCorp, not hospital outpatient, to minimize lab costs. LabCorp's patient pricing page lists the fasting lipid panel at approximately $34 for self-pay patients nationally.

For an uninsured Arkansas patient, the total monitoring cost across a 20-week course (baseline plus two follow-up panels) may add $90, $300 to overall treatment cost. Telehealth platforms that include lab orders should specify a low-cost outpatient lab to keep this figure manageable.

Side Effects That Affect Cost Calculations

Side effects of isotretinoin can add indirect costs. Dry skin and cheilitis affect nearly all patients; a basic petrolatum-based lip balm and fragrance-free moisturizer cost $10, $25 per month at any Arkansas dollar store or pharmacy. Reyes-Habito and Tan (Int J Dermatol, 2014; PMID 24164652) documented that mucocutaneous side effects occur in over 90% of isotretinoin users, with cheilitis being the most consistent.

Musculoskeletal pain, elevated triglycerides, and mood changes may each prompt additional clinical visits or interventions. Severe hypertriglyceridemia (triglycerides above 500 mg/dL) occurs in roughly 25% of patients on standard doses and may require dose reduction or temporary discontinuation. Zane et al. (Arch Dermatol, 2006; PMID 16490845) found that triglyceride elevation was the most common lab abnormality requiring management during isotretinoin courses.

Budgeting for these additional items is part of an honest total-cost calculation. A patient who plans for $350/month in drug cost alone may be surprised by $60, $150/month in ancillary expenses across a full course.

Comparing All Arkansas Pricing Pathways Side by Side

The table below summarizes the major pricing pathways available to Arkansas patients in 2026. Prices are estimates based on 2026 pharmacy data and may vary.

| Pathway | Estimated Monthly Cost | Notes | |---|---|---| | Cash pay, no discount | $800, $1,200 | List price; avoid if possible | | Cash pay with GoodRx/RxSaver | $100, $350 | Varies by ZIP code and pharmacy | | Arkansas Medicaid (PA approved) | $0, $3 | Preferred generic only; PA required | | Commercial insurance (Tier 2 copay) | $45, $130 | PA may apply for higher-tier products | | Compounded isotretinoin (503A) | $0, $150 | Clinical rationale and lab testing required | | Manufacturer PAP (uninsured, income-eligible) | $0 | 2-week application process | | 340B FQHC pharmacy | Substantially below retail | Must receive care at 340B-covered site |

Frequently Asked Questions